These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33822122)

  • 1. Novel therapeutic approaches for Parkinson's disease by targeting brain cholesterol homeostasis.
    Pingale TD; Gupta GL
    J Pharm Pharmacol; 2021 Jun; 73(7):862-873. PubMed ID: 33822122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease.
    Doria M; Maugest L; Moreau T; Lizard G; Vejux A
    Free Radic Biol Med; 2016 Dec; 101():393-400. PubMed ID: 27836779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment.
    Fanning S; Haque A; Imberdis T; Baru V; Barrasa MI; Nuber S; Termine D; Ramalingam N; Ho GPH; Noble T; Sandoe J; Lou Y; Landgraf D; Freyzon Y; Newby G; Soldner F; Terry-Kantor E; Kim TE; Hofbauer HF; Becuwe M; Jaenisch R; Pincus D; Clish CB; Walther TC; Farese RV; Srinivasan S; Welte MA; Kohlwein SD; Dettmer U; Lindquist S; Selkoe D
    Mol Cell; 2019 Mar; 73(5):1001-1014.e8. PubMed ID: 30527540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics.
    Davies KM; Mercer JF; Chen N; Double KL
    Clin Sci (Lond); 2016 Apr; 130(8):565-74. PubMed ID: 26957644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol - A putative endogenous contributor towards Parkinson's disease.
    Paul R; Choudhury A; Borah A
    Neurochem Int; 2015 Nov; 90():125-33. PubMed ID: 26232622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
    Lingor P; Carboni E; Koch JC
    J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aquaporin-4 and Parkinson's Disease.
    Lapshina KV; Ekimova IV
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
    Rott R; Szargel R; Shani V; Bisharat S; Engelender S
    CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?
    Marwarha G; Ghribi O
    Exp Gerontol; 2015 Aug; 68():13-8. PubMed ID: 25261765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.
    Fowler AJ; Moussa CE
    CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.
    Bisaglia M; Greggio E; Beltramini M; Bubacco L
    FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
    Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG
    Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.
    Galvagnion C
    J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
    Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
    J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered lipid metabolism in brain injury and disorders.
    Adibhatla RM; Hatcher JF
    Subcell Biochem; 2008; 49():241-68. PubMed ID: 18751914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein oligomers: a new hope.
    Bengoa-Vergniory N; Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Acta Neuropathol; 2017 Dec; 134(6):819-838. PubMed ID: 28803412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.
    Bar-On P; Crews L; Koob AO; Mizuno H; Adame A; Spencer B; Masliah E
    J Neurochem; 2008 Jun; 105(5):1656-67. PubMed ID: 18248604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibitors of α-synuclein for the treatment of Parkinson's disease: a patent landscape.
    Joubert J
    Pharm Pat Anal; 2020 May; 9(3):63-65. PubMed ID: 32602809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.